Vivoryon Therapeutics AG Stock Euronext Amsterdam
Equities
DE0007921835
Biotechnology & Medical Research
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 14.86M 15.84M |
---|---|---|---|---|---|
Net income 2023 * | -23M -24.53M | Net income 2024 * | -18M -19.2M | EV / Sales 2023 * | - |
Net cash position 2023 * | 24.1M 25.7M | Net cash position 2024 * | 19.55M 20.85M | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.61
x | P/E ratio 2024 * |
-0.8
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.82% |
Latest transcript on Vivoryon Therapeutics AG
Managers | Title | Age | Since |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 18-08-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 74 | 06-12-31 | |
Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
1st Jan change | Capi. | |
---|---|---|
-0.02% | 42.11B | |
+46.11% | 40.08B | |
+5.04% | 40B | |
-11.32% | 26.87B | |
+5.25% | 24.58B | |
-23.83% | 18.44B | |
-1.62% | 11.94B | |
+22.75% | 11.66B | |
+6.44% | 11.01B |